An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD

Obsessive Compulsive Disorder Clinical Trial

Official title:

A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02229903
• Other study ID #: CTP-OCD-01
• Status: Completed
• Phase: N/A
• Start date: September 2014
• Est. completion date: June 2017

Study information

• Verified date: February 2017
• Source: Brainsway
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and efficacy of the Deep TMS (DTMS) treatment in subjects with OCD. The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a predetermined frequency. The Brainsway DTMS study is a randomized, 10 week, double blind, multi-center trial comparing active DTMS treatment to sham treatment.

Description:

The OCD study will compare one group of OCD subjects receiving DTMS treatment (HAC-coil) to a second group of OCD subjects receiving sham treatment (sham coil). The treatment group will receive 5 weeks of daily DTMS treatments followed by 4 treatments in week 6, for a total of 29 treatment sessions. The control group will receive the same treatments with a sham coil. Subjects may continue to take SSRI medications (if prescribed) and any other antidepressant medications will be tapered down prior to the first treatment. SSRI medications approved for OCD include Fluoxetine (Prozac, Sarafem, Symbyax), Fluvoxamine (Luvox, Luvox CR), Paroxetine (Paxil, Paxil CR, Pexeva) and Sertraline (Zoloft). Efficacy will be assessed using the Yale-Brown Obsessive Compulsive Scale score (YBOCS), as well as other efficacy scales. Safety will be assessed by monitoring of adverse events, vital signs, physical and neurological examination and using certain safety questionnaires.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 68 Years

Eligibility

Inclusion Criteria:

• • Outpatients

• Men and women 22-68 years of age.

• Subjects diagnosed as suffering from OCD according to the DSM-IV-TR.

• Subjects with at least moderate OCD, rating a YBOCS score of >20.

• Subjects are maintained on SSRI medication at at least a therapeutic dosage for at least 2 months prior to study entry and for the duration of the trial and/or subjects are maintained on psychotherapeutic behavioral intervention therapy (subjects undergoing CBT treatment must be in the maintenance stage (i.e., not during the assessment or skills acquisition or training stages).

• Subjects with negative responses on the Transcranial Magnetic Stimulation Safety Screening questionnaire (TASS).

• According to the treating physician the subject is compliant with taking medication, if applicable.

• Subject is capable and willing to provide informed consent.

• Subject is able to adhere to the treatment schedule.

Exclusion Criteria:

• • Subjects diagnosed according to the SCID I as suffering from any other Axis I diagnosis as the primary diagnosis.

• Subjects diagnosed according to the SCID II as suffering from severe Personality Disorder (excluding Obsessive Compulsive Personality Disorder) or hospitalized due to exacerbation related to borderline personality disorder.

• Present suicidal risk as assessed by the investigator using the Scale for Suicide Ideation (SSI), brief mental status exam and psychiatric interview or significant suicide risk based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide in the past year.

• Subject has a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT) or history of such in first degree relatives.

• Subject has an increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.

• Subject has a history of head injury necessitating cranial surgery or prolonged coma.

• Subject has a history of any metal in the head including the eyes and ears (outside the mouth).

• Subject has known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.

• Subject has a history of significant hearing loss.

• Subjects with significant neurological disorder or insult including, but not limited to:

• Any condition likely to be associated with increased intracranial pressure

• Subject has a history of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine).

• Inadequate communication with the patient.

• Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study.

• Subjects who suffer from an unstable physical, systemic and metabolic disorder such as unstabilized blood pressure or acute, unstable cardiac disease.

• Subject is currently on any antidepressant medication other than SSRIs.

• Subject is currently on Clomipramine

• Subject has had previous treatment with TMS

• Women who are breast-feeding

• Women who are pregnant or with suspected pregnancy

• Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.

Related Conditions & MeSH terms

• Obsessive Compulsive Disorder
• Obsessive-Compulsive Disorder

Intervention

Device:
• Active DTMS Treatment
H-coil Deep TMS 29 TMS treatments over 6 weeks.
• Sham Treatment
29 treatments over 6 weeks.

Locations

Country	Name	City	State
Canada	Center for Addiction and Mental Health (CAMH)	Toronto	Ontario
Israel	Tel Hashomer Hospital	Tel Hashomer
United States	University of Chicago	Chicago	Illinois
United States	University of Florida College of Medicine	Gainesville	Florida
United States	Advanced Mental Health Care Inc. - Juno Beach	Juno Beach	Florida
United States	University of California (UCLA)	Los Angeles	California
United States	Lindner Center of HOPE, University of Cincinnati College of Medicine	Mason	Ohio
United States	Mount Sinai Hospital	New York	New York
United States	Neuropharmacology Services	New York	New York
United States	TMS Hope Center of Long Island	New York	New York
United States	Advanced Mental Health Care Inc. - Royal Palm Beach	Royal Palm Beach	Florida
United States	University of California	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Brainsway

Countries where clinical trial is conducted

United States,  Canada,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of adverse events, changes in vitals signs, physical and neurological results, changes in suicide scale and changes in cognitive scales	Safety of the DTMS treatment as defined by maintained subject baseline, pre-treatment, physical and neurological examinations and lack of significant increase in suicide ideation measured by: Vital signs; Physical and neurological examination; Scale for Suicide Ideation; Cognitive evaluation using the Mini-Mental State Exam (MMSE), Buschke Selective Reminding Test (BSRT) and Autobiographical Memory Interview - Short Form (AMI-S) scales; Any other adverse events (AEs).	10 Weeks
Primary	Yale Brown Obsessive Compulsive Scale (YBOCS) score	The primary objective of the study is to compare the change in Yale Brown Obsessive Compulsive Scale (YBOCS) scores from baseline to the 6 week (post-randomization) visit, between the two treatments groups.	6 Weeks
Secondary	Yale Brown Obsessive Compulsive Scale (YBOCS), Sheehan Disability Scale (SDS), Clinical Global Impression - Severity Scale (CGI-S), Clinical Global Impression - Improvement Scale (CGI-I)	The secondary effectiveness objectives of the study are: i. Change from baseline to 6 weeks in Yale Brown Obsessive Compulsive Scale (YBOCS) (and other assessment scale) scores, between treatment groups.; ii. Response rate at 6 weeks in Yale Brown Obsessive Compulsive Scale (YBOCS) score from baseline, between treatment groups; iii.Partial Response rate at 6 weeks in Yale Brown Obsessive Compulsive Scale (YBOCS) score, between treatment groups; iv. Change from baseline to 10 weeks in above scales. v. Remission rates at 6 weeks between treatment groups.	6 Weeks and 10 weeks